BriaCell Therapeutics Corp. EBITDA for the year ending July 31, 2023: USD -22.37 M

BriaCell Therapeutics Corp. EBITDA is USD -22.37 M for the year ending July 31, 2023, a -34.31% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • BriaCell Therapeutics Corp. EBITDA for the year ending July 31, 2022 was USD -34.05 M, a 94.70% change year over year.
  • BriaCell Therapeutics Corp. EBITDA for the year ending July 31, 2021 was USD -17.49 M.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)